Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2002 4
2003 3
2004 2
2005 2
2007 4
2008 3
2009 2
2010 3
2011 4
2014 2
2015 4
2016 1
2017 1
2018 3
2019 5
2020 7
2021 9
2022 15
2023 23
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Results by year

Filters applied: . Clear all
Page 1
Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate.
Uraki R, Ito M, Kiso M, Yamayoshi S, Iwatsuki-Horimoto K, Furusawa Y, Sakai-Tagawa Y, Imai M, Koga M, Yamamoto S, Adachi E, Saito M, Tsutsumi T, Otani A, Kikuchi T, Yotsuyanagi H, Halfmann PJ, Pekosz A, Kawaoka Y. Uraki R, et al. Among authors: tsutsumi t. Lancet Infect Dis. 2023 Apr;23(4):402-403. doi: 10.1016/S1473-3099(23)00070-1. Epub 2023 Feb 8. Lancet Infect Dis. 2023. PMID: 36773622 Free PMC article. No abstract available.
Ursodeoxycholic acid for coronavirus disease 2019 prevention.
Okushin K, Kurano M; UTH-UDCA Study Group; Yatomi Y, Moriya K, Fujishiro M, Tsutsumi T. Okushin K, et al. Among authors: tsutsumi t. J Intern Med. 2024 Jan;295(1):106-109. doi: 10.1111/joim.13704. Epub 2023 Jul 27. J Intern Med. 2024. PMID: 37470083 No abstract available.
Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1.
Uraki R, Ito M, Kiso M, Yamayoshi S, Iwatsuki-Horimoto K, Sakai-Tagawa Y, Furusawa Y, Imai M, Koga M, Yamamoto S, Adachi E, Saito M, Tsutsumi T, Otani A, Kashima Y, Kikuchi T, Yotsuyanagi H, Suzuki Y, Kawaoka Y. Uraki R, et al. Among authors: tsutsumi t. Lancet Infect Dis. 2023 May;23(5):525-526. doi: 10.1016/S1473-3099(23)00132-9. Epub 2023 Mar 7. Lancet Infect Dis. 2023. PMID: 36898405 Free PMC article. No abstract available.
Antiviral effect and safety of nafamostat mesilate in patients with mild early-onset COVID-19: An exploratory multicentre randomized controlled clinical trial.
Okugawa S, Ikeda M, Kashiwabara K, Moritoyo T, Kohsaka T, Shimizu T, Hagiya H, Hasegawa K, Otsuka F, Miwa A, Kisimoto N, Mizoguchi A, Imamura A, Ikeuchi K, Tsutsumi T, Jubishi D, Hashimoto H, Okamoto K, Harada S, Inoue JI, Seto Y, Moriya K. Okugawa S, et al. Among authors: tsutsumi t. Int J Antimicrob Agents. 2023 Sep;62(3):106922. doi: 10.1016/j.ijantimicag.2023.106922. Epub 2023 Jul 8. Int J Antimicrob Agents. 2023. PMID: 37429450 Free article. Clinical Trial.
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2.
Uraki R, Kiso M, Iida S, Imai M, Takashita E, Kuroda M, Halfmann PJ, Loeber S, Maemura T, Yamayoshi S, Fujisaki S, Wang Z, Ito M, Ujie M, Iwatsuki-Horimoto K, Furusawa Y, Wright R, Chong Z, Ozono S, Yasuhara A, Ueki H, Sakai-Tagawa Y, Li R, Liu Y, Larson D, Koga M, Tsutsumi T, Adachi E, Saito M, Yamamoto S, Hagihara M, Mitamura K, Sato T, Hojo M, Hattori SI, Maeda K, Valdez R; IASO study team; Okuda M, Murakami J, Duong C, Godbole S, Douek DC, Maeda K, Watanabe S, Gordon A, Ohmagari N, Yotsuyanagi H, Diamond MS, Hasegawa H, Mitsuya H, Suzuki T, Kawaoka Y. Uraki R, et al. Among authors: tsutsumi t. Nature. 2022 Jul;607(7917):119-127. doi: 10.1038/s41586-022-04856-1. Epub 2022 May 16. Nature. 2022. PMID: 35576972 Free PMC article.
Antiviral efficacy against and replicative fitness of an XBB.1.9.1 clinical isolate.
Uraki R, Ito M, Kiso M, Yamayoshi S, Iwatsuki-Horimoto K, Sakai-Tagawa Y, Imai M, Koga M, Yamamoto S, Adachi E, Saito M, Tsutsumi T, Otani A, Fukushi S, Watanabe S, Suzuki T, Kikuchi T, Yotsuyanagi H, Maeda K, Kawaoka Y. Uraki R, et al. Among authors: tsutsumi t. iScience. 2023 Oct 4;26(11):108147. doi: 10.1016/j.isci.2023.108147. eCollection 2023 Nov 17. iScience. 2023. PMID: 37876803 Free PMC article.
Efficacy of antivirals and mRNA vaccination against an XBF clinical isolate.
Uraki R, Ito M, Kiso M, Yamayoshi S, Iwatsuki-Horimoto K, Sakai-Tagawa Y, Imai M, Koga M, Yamamoto S, Adachi E, Saito M, Tsutsumi T, Otani A, Kashima Y, Kikuchi T, Theiler J, Yotsuyanagi H, Suzuki Y, Korber B, Kawaoka Y. Uraki R, et al. Among authors: tsutsumi t. Lancet Reg Health West Pac. 2023 May;34:100777. doi: 10.1016/j.lanwpc.2023.100777. Epub 2023 May 11. Lancet Reg Health West Pac. 2023. PMID: 37193320 Free PMC article. No abstract available.
Differences among epitopes recognized by neutralizing antibodies induced by SARS-CoV-2 infection or COVID-19 vaccination.
Yamamoto S, Yamayoshi S, Ito M, Sakai-Tagawa Y, Nakachi I, Baba R, Kamimoto S, Ogura T, Hagiwara S, Kato H, Nakajima H, Uwamino Y, Yagi K, Sugaya N, Nagai H, Saito M, Adachi E, Koga M, Tsutsumi T, Duong C, Okuda M, Murakami J, Furusawa Y, Ujie M, Iwatsuki-Horimoto K, Yotsuyanagi H, Kawaoka Y. Yamamoto S, et al. Among authors: tsutsumi t. iScience. 2023 Jun 25;26(7):107208. doi: 10.1016/j.isci.2023.107208. eCollection 2023 Jul 21. iScience. 2023. PMID: 37448563 Free PMC article.
91 results